CDKN2A and acute lymphoblastic leukemia: This mutation contributes to the silencing of cyclin-dependent kinase inhibitor 2A (CDKN2A) and the aberrant expression of cytokine receptor-like factor 2 (CRLF2) in the development of BCP-ALL [53,56].